Pharmacological Neuroprotection and Clinical Trials of Novel Therapies for Neonatal Peri-Intraventricular Hemorrhage: A Comprehensive Review
Acta Neurologica Belgica
Peri-intraventricular hemorrhage (PIVH) is a serious condition for preterm infants, caused by traumatic or spontaneous rupture of the germinal matrix (GM) capillary network in the cerebral ventricles. It is a common source of morbidity and mortality in neonates, and risk correlates with earlier delivery, low birth weight, maternal-fetal infection, and vital sign derangements, among others. PIVH typically occurs in the first 72 h of life, and symptoms, when present, manifest most commonly within the first week of life. Prevention remains the primary goal in management, predominantly via prolonging of gestation. Current therapy protocols are center-dependent without consistent consensus guidelines, but infant positioning, homeostatic stabilization, and neuroprotection offer potential options. In this update of pharmacologic neuroprotective therapies for PIVH, we highlight commonly utilized therapies and review the investigative literature. Further multi-institutional clinical trials and basic research studies are required.
Infant, narrative review, neonatal intraventricular hemorrhage, neurocognition, neuroprotection, pediatric neurosurgery
Reardon T, Koller GM, Kortz MW, McCray E, Wittenberg B, Hankinson T. Pharmacological Neuroprotection and Clinical Trials of Novel Therapies for Neonatal Peri-Intraventricular Hemorrhage: A Comprehensive Review. Acta Neurologica Belgica. 2022; 122(2). doi: 10.1007/s13760-022-01889-1.